Yahoo · Oct 1, 2026
Best Value Stocks to Buy for October 1st
BP and PBH made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 1, 2026.
NYSE · PBH
Prestige Consumer Healthcare Inc.
Healthcare · Medical - Distribution
$46.44
Up+$0.84 (+1.84%)
Updated Oct 7, 2026, 12:24 PM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.01B
- P/E ratio
- 14.86
- Dividend yield
- 0.00%
- 52-week range
- $42.62 – $67.00
- Volume
- 660.93K
- Avg. volume
- 457.59K
Price performance · PBH
PBH price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PBH closed at $46.44 after 21 trading sessions, down 6.73% for the selected period.
- Last close
- $46.44
- Period change
- -6.73%
- Period low
- $44.77
- Period high
- $49.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $45.90 | $46.61 | $45.58 | $46.44 | 660.93K |
| Oct 5, 2026 | $45.11 | $45.875 | $44.77 | $45.60 | 604.39K |
| Oct 2, 2026 | $44.88 | $45.7486 | $44.60 | $45.26 | 543.3K |
| Oct 1, 2026 | $45.76 | $46.13 | $44.64 | $44.77 | 731.39K |
| Sep 30, 2026 | $46.69 | $46.69 | $45.85 | $45.87 | 583.49K |
| Sep 29, 2026 | $46.73 | $46.85 | $46.04 | $46.74 | 566.7K |
| Sep 28, 2026 | $46.25 | $47.33 | $46.2434 | $46.93 | 651.76K |
| Sep 25, 2026 | $45.34 | $46.72 | $44.97 | $46.61 | 467.65K |
| Sep 24, 2026 | $46.12 | $46.49 | $45.30 | $45.65 | 627.22K |
| Sep 23, 2026 | $47.45 | $47.455 | $45.91 | $45.92 | 503.99K |
| Sep 22, 2026 | $47.55 | $47.80 | $47.02 | $47.73 | 619.56K |
| Sep 21, 2026 | $45.01 | $47.00 | $44.46 | $46.80 | 660.42K |
| Sep 18, 2026 | $46.29 | $46.395 | $44.88 | $44.97 | 2.02M |
| Sep 17, 2026 | $47.20 | $47.485 | $45.90 | $46.47 | 504.03K |
| Sep 16, 2026 | $46.83 | $47.685 | $46.49 | $46.86 | 536.93K |
| Sep 15, 2026 | $47.22 | $48.25 | $46.38 | $46.68 | 767.13K |
| Sep 14, 2026 | $47.91 | $48.42 | $47.17 | $47.62 | 580.76K |
| Sep 11, 2026 | $47.68 | $47.75 | $46.4834 | $46.95 | 495.64K |
| Sep 10, 2026 | $49.37 | $49.51 | $47.29 | $47.34 | 513.59K |
| Sep 9, 2026 | $49.53 | $49.87 | $48.17 | $48.70 | 474.87K |
| Sep 8, 2026 | $51.67 | $51.67 | $49.73 | $49.79 | 418.33K |
Latest PBH news
The latest Smart Investors Daily articles mentioning PBH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PBH research
Overview
Company profile and research snapshot.
Company profile
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $71.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 15, 2026 | Canaccord Genuity | Buy | — |
| May 14, 2026 | Oppenheimer | Perform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Feb 2, 2026 | Jefferies | Hold | — |
| Nov 7, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds
Women may be talking more openly about intimate health and wellness, but that does not necessarily mean the discomfort has disappeared. New research from Summer's Eve® finds that while nearly two-thirds of U.S. women (63%) believe women today are more comfortable openly discussing intimate health and wellness than they were five years ago, more than half (52%) have personally avoided talking to someone about an intimate health and wellness concern because they felt embarrassed or uncomfortable.
Yahoo · Sep 29, 2026
Has Prestige Consumer Healthcare (PBH) Fallen Far Enough On Earnings?
Prestige Consumer Healthcare has seen its share price under pressure over the past year, and that kind of slide naturally puts the spotlight on what investors are paying for its earnings today. The question now is whether the current valuation of Prestige Consumer Healthcare's profit stream still makes sense given how the business is executing. The stock has fallen 24.2% over the past year, which raises the issue of whether the current earnings multiple properly reflects what the company is...
Yahoo · Sep 29, 2026
Prestige Consumer Healthcare (PBH) Could Be 30% Undervalued After Its 2027 Targets
Prestige Consumer Healthcare (PBH) recently outlined medium term targets for fiscal 2027, putting fresh attention on its over the counter portfolio, free cash flow priorities, and the impact of Clear Eyes supply constraints. Prestige Consumer Healthcare’s recent medium term outlook lands after a tougher stretch in the market, with the share price down 23.34% year to date and the 1 year total shareholder return declining 24.25%, while the 30 day share price return has fallen 10.56%. This...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
